Cumberland Pharmaceuticals Inc., oo ah shirkad dawo oo khaas ah, ayaa maanta ku dhawaaqday Maamulka Cunnada iyo Dawooyinka ee Maraykanka (FDA) ayaa oggolaaday calaamadaynta balaadhinta ee Caldolor®, oo ah qaab xididada xididka laga siiyo ee ibuprofen, oo hadda lagu daro isticmaalka maamulka qalliinka ka hor.
Summada cusub ee FDA-ansixisay waxaa ka mid ah macluumaadka ku saabsan tilmaamaha iyo isticmaalka badeecada, bukaannada ku habboon, natiijooyinka daraasadda bukaan-socodka, waxyeellooyinka ka iman kara, faahfaahinta badbaadada bukaanka, iyo tilmaamaha isticmaalka haweenka uurka leh, carruurta iyo dadka kale.
Taageerida isticmaalka balaarinta Caldolor, daraasad lagu sameeyay xanuunka qalliinka lafaha ayaa xaqiijisay dhimista xanuunka weyn marka badeecada la maamulay lixdii saacadoodba mar (la bilaabay qaliin kahor) oo leh morphine dheeri ah oo la heli karo iyadoo loo eegayo baahida loo qabo. Wadarta 185 bukaan ayaa la kala soocay waxaana lagu daweeyay Caldolor® 800 mg ama placebo midkood lixdii saacadoodba mar (la bilaabay qalliin ka hor) iyo morphine ayaa la bixiyay iyadoo loo eegayo baahida loo qabo.
Waxtarka ayaa lagu muujiyay sida tirakoob ahaan aad u weyn oo hoos u dhac ku yimid xoojinta xanuunka saacadaha 24 ka dib qalliinka bukaanada lagu daaweeyay Caldolor® marka la barbardhigo kuwa qaata placebo.
MAXAA LAGU QAADAYAA MAQAALKAN:
- Supporting this expanded use of Caldolor, a study of orthopedic surgical pain confirmed the significant pain reduction when the product was administered every six hours (started pre-operatively) with supplemental morphine available on an as needed basis.
- A total of 185 patients were randomized and treated with either Caldolor® 800 mg or placebo administered every six hours (started pre-operatively) and morphine provided on an as needed basis.
- Waxtarka ayaa lagu muujiyay sida tirakoob ahaan aad u weyn oo hoos u dhac ku yimid xoojinta xanuunka saacadaha 24 ka dib qalliinka bukaanada lagu daaweeyay Caldolor® marka la barbardhigo kuwa qaata placebo.
